[Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010)- study AB 53/15 of the AUO]

Urologe A. 2016 Nov;55(11):1491-1493. doi: 10.1007/s00120-016-0248-5.
[Article in German]
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / administration & dosage
  • Chemotherapy, Adjuvant / methods
  • Cystectomy / methods*
  • Disease-Free Survival
  • Female
  • Germany
  • Humans
  • Male
  • Middle Aged
  • Muscle, Smooth / pathology
  • Neoplasm Invasiveness
  • Risk Factors
  • Survival Rate
  • Treatment Outcome
  • Urinary Bladder Neoplasms / diagnosis
  • Urinary Bladder Neoplasms / pathology*
  • Urinary Bladder Neoplasms / therapy*
  • Watchful Waiting / methods*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • atezolizumab